Previous 10 | Next 10 |
Shares of Guardant Health (NASDAQ: GH) jumped 12% on Friday following the company's announcement of its third-quarter results after the market closed on Thursday. Guardant Health reported that its revenue skyrocketed 181% year over year in Q3 to $60.8 million. The company posted a net loss o...
Guardant Health (NASDAQ: GH ) is up 11% premarket on light volume following its Q3 results released after the close yesterday. Highlights: More news on: Guardant Health, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Guardant Health (NASDAQ: GH ): Q3 GAAP EPS of -$0.14 beats by $0.23 . Revenue of $60.8M (+180.3% Y/Y) beats by $15.4M . Shares +3.7% . Press Release More news on: Guardant Health, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news,
REDWOOD CITY, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for...
Guardant Health (NASDAQ: GH ) is a $6 billion+ market capitalization precision oncology testing company that is developing some exciting new technology in the cancer space. The company announced the closing of its initial public offering on October 9 of last year, raising just over $270 millio...
Guardant Health (NASDAQ: GH ) is scheduled to announce Q3 earnings results on Thursday, November 7th, after market close. The consensus EPS Estimate is -$0.37 (+80.9% Y/Y) and the consensus Revenue Estimate is $45.4M (+109.3% Y/Y). Over the last 3 months, EPS estimates have seen 4 upw...
REDWOOD CITY, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the third quarter 2019 after market close on Thursday, November 7, 2019. Company management will host a corresponding conference call beginning at ...
REDWOOD CITY, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) has initiated the ECLIPSE trial, a 10,000-patient registrational study to evaluate the performance of its LUNAR-2 blood test to detect colorectal cancer (CRC) in average-risk adults. The test is inten...
Advances in chemistry, process engineering, and computing power have led to incredible advances in DNA sequencing and our understanding of the human genome. Much digital ink has been spilled discussing the investing opportunities within the field of genomics, which studies the structure and fu...
Investing in stocks can make you rich. Just how rich and just how quickly you become wealthy varies considerably, of course. The important thing is to pick the right stocks that give you the best shot at delivering exceptional returns over a period of at least 10 years. Three stocks that I...
News, Short Squeeze, Breakout and More Instantly...
Tuesday, the FDA's staff reviewers raised concerns regarding Guardant Health Inc's (NASDAQ:GH) experimental bloo...
Blood-based test for comprehensive genomic profiling of solid cancers meets requirements under stricter EU In Vitro Diagnostic Regulation IVDR certification from TÜV SÜD enables broader adoption of guideline-recommended genomic profiling to inform optimal therapy selection for p...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (C...